Pharmaceutical Manufacturing And Innovation Projects Speed Up
This article was originally published in PharmAsia News
Executive Summary
According to the China Pharmaceutical Technology Transfer Center and the China Pharmaceutical Technology Organization, a Dec. 7 national advanced pharmaceutical technology management training class will focus on process management in the pharmaceutical manufacturing and innovation project (PharmAsia News, Sep. 8, 2008) under the country's 11th Five-Year Plan (2006-2010). At present, work on the first batch of project applications has been completed and the acceptance list will be publicized soon. A total of 3,290 proposed projects for the second batch are under appraisal and classes will begin next year. Subjects cover pivotal technology research in new drug development, establishment of technology platforms for drug innovation and construction of new drug incubation centers for enterprises. (Click here for more - Chinese Language)
You may also be interested in...
China Kicks Off Pharmaceutical Manufacturing And Innovation Project
A task force comprising members from China's Ministry of Health and 10 governmental bodies has proposed pharmaceutical manufacturing and innovation guidelines under the national science and technology development program. The project has two key targets, first of which is the development of a batch of medical products that are safe, efficient, convenient and cheap to prevent and treat major diseases. The second is the development of innovative drugs with intellectual property rights and market competitiveness, building up of advanced technology platforms, as well as shaping new drug creativity and technology systems to support the nation's pharmaceutical innovation. (Click here for more - Chinese Language)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.